Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
14.73
+0.29 (2.01%)
At close: May 13, 2026, 4:00 PM EDT
14.77
+0.04 (0.27%)
After-hours: May 13, 2026, 7:25 PM EDT
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
1.91B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Lakefront Biotherapeutics NV | 558 |
| Syndax Pharmaceuticals | 298 |
| Capricor Therapeutics | 231 |
| Pharvaris | 129 |
| Inhibrx Biosciences | 110 |
| AnaptysBio | 104 |
| Rapport Therapeutics | 84 |
MESO News
- 14 days ago - Mesoblast (MESO) Reports Strong Q1 Sales for Ryoncil® - GuruFocus
- 14 days ago - Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - GlobeNewsWire
- 15 days ago - Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 4 weeks ago - Mesoblast Acquires CAR Technology From Mayo Clinic To Enhance MSC Therapies - Nasdaq
- 4 weeks ago - Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up - Nasdaq
- 4 weeks ago - Mesoblast (MESO) Secures Global License for Advanced CAR Technology - GuruFocus
- 4 weeks ago - Mesoblast acquires chimeric antigen receptor platform technology - TheFly
- 4 weeks ago - Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - GlobeNewsWire